Skip to main content
HR 6672 112th Congress House Health Administrative law and regulatory procedures Advanced technology and technological innovations Advisory bodies Chemical and biological weapons Child health Congressional oversight Department of Health and Human Services Department of Veterans Affairs Drug safety, medical device, and laboratory regulation Emergency medical services and trauma care Emergency planning and evacuation Executive agency funding and structure Food and Drug Administration (FDA) Government employee pay, benefits, personnel management Government information and archives Government studies and investigations Health facilities and institutions Health information and medical records Health personnel

Pandemic and All-Hazards Preparedness Reauthorization Act of 2012

Introduced: December 17, 2012 See on congress.gov
Sign in to write a letter Sign in to watch
 Everywhere this bill has been 12 steps
Introduced
In committee
Reported out
Passed House
Passed Senate
To President
Became law
Jan 2, 2013
Referred to the Subcommittee on Health.
Dec 19, 2012
Received in the Senate.
Dec 19, 2012
Motion to reconsider laid on the table Agreed to without objection.
Dec 19, 2012
On motion to suspend the rules and pass the bill Agreed to by the Yeas and Nays: (2/3 required): 383 - 16 (Roll no. 633). (text: CR H7282-7292)
Dec 19, 2012
Passed/agreed to in House: On motion to suspend the rules and pass the bill Agreed to by the Yeas and Nays: (2/3 required): 383 - 16 (Roll no. 633).(text: CR H7282-7292)
Dec 19, 2012
Considered as unfinished business. (consideration: CR H7307)
Dec 19, 2012
At the conclusion of debate, the Yeas and Nays were demanded and ordered. Pursuant to the provisions of clause 8, rule XX, the Chair announced that further proceedings on the motion would be postponed.
Dec 19, 2012
DEBATE - The House proceeded with forty minutes of debate on H.R. 6672.
Dec 19, 2012
Considered under suspension of the rules. (consideration: CR H7282-7296)
Dec 19, 2012
Mr. Rogers (MI) moved to suspend the rules and pass the bill.
Dec 17, 2012
Referred to the Committee on Energy and Commerce, and in addition to the Committee on Veterans' Affairs, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
Dec 17, 2012
Introduced in House
 Votes taken on this bill 1
DateChamberWhat was voted onResultYes–No
Dec 19, 2012 House · vote #633 On Motion to Suspend the Rules and Pass Passed 383–16 See who voted →
 Plain-English summary Congressional Research Service

Pandemic and All-Hazards Preparedness Act Reauthorization of 2012 - Amends the Public Health Service Act (PHSA) to require the Secretary of Health and Human Services (HHS) to submit the National Health Security Strategy to Congress in 2014.

Gives the Assistant Secretary for Preparedness lead responsibility within HHS for emergency preparedness and response policy and coordination.

Requires the Secretary to establish the National Advisory Committee on Children and Disasters.

Reauthorizes appropriations for public health preparedness activities, including: (1) the National Disaster Medical System, (2) the public health emergency readiness of the Department of Veterans Affairs (VA) medical centers, (3) state and local public health security, (4) the influenza vaccine tracking and distribution program, (5) the Emergency System for Advance Registration of Health Professions Volunteers (ESAR-VHP), (6) the Medical Reserve Corps, (7) surge capacity and community and hospital preparedness, (7) public health alert communications and surveillance and public health situational awareness capability, (8) the Special Reserve Fund, (8) the Biomedical Advanced Research and Development Authority (BARDA), and (9) the Strategic National Stockpile.

Amends the Federal Food, Drug, and Cosmetic Act to give the Secretary additional powers during a public health emergency related to: (1) the use of unapproved medical products or the unapproved use of an approved product, (2) the extension of the expiration date of eligible medical countermeasures, (3) deviations from good manufacturing practice requirements, (4) waiver of prescription requirements, and (5) waiver of requirements for a risk evaluation and mitigation strategy.

Requires the Secretary to establish a formal process for obtaining scientific feedback and interactions regarding the development and regulatory review of eligible countermeasures through written regulatory management plans.

Sets forth requirements regarding pediatric studies for medical countermeasures.

Extends the Freedom of Information Act (FOIA) exemption for specific technical data or scientific information that is created or obtained during countermeasure and product advanced research and development carried out under PHSA that reveals significant and not otherwise known vulnerabilities of existing medical or public health defenses against biological, chemical, nuclear, or radiological threats.

Extends the antitrust exemption to permit meetings and consultations to discuss the development of security countermeasures, qualified countermeasures, or qualified pandemic or epidemic products.

What's happening now January 2, 2013

Referred to the Subcommittee on Health.

 Committees of jurisdiction 3
 Cosponsors 1
All 1 Democratic 1